CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,975.70 | 35.30 | 0.39% |
| CAC 40 | 7,868.05 | 88.65 | -1.11% |
| DAX 40 | 25,319.77 | 302.84 | -1.18% |
| Dow JONES (US) | 52,059.62 | 57.21 | 0.11% |
| FTSE 100 | 10,764.69 | 117.21 | -1.08% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,571.34 | 431.30 | 1.65% |
| Nikkei 225 | 64,916.70 | 407.59 | -0.62% |
| NZX 50 Index | 13,652.07 | 101.66 | -0.74% |
| S&P 500 | 7,719.97 | 60.53 | 0.79% |
| S&P/ASX 200 | 8,845.70 | 39.00 | 0.44% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |